Viral Infection and The Discovery and Mode of Action of Novel Antivirals

A special issue of Microorganisms (ISSN 2076-2607). This special issue belongs to the section "Virology".

Deadline for manuscript submissions: 31 July 2025 | Viewed by 350

Special Issue Editor


E-Mail Website
Guest Editor
Rega Institute, Department of Microbiology, Immunomogy & Transplantation, KU Leuven, Leuven, Belgium
Interests: virology; DNA viruses; antivirals; drug resistance
Special Issues, Collections and Topics in MDPI journals

Special Issue Information

Dear Colleagues,

The infectious disease landscape is constantly evolving, with viral infections posing a significant threat to global health. New antiviral agents can combat emerging and re-emerging viral threats. This Special Issue aims to collate the latest research and reviews on the mechanisms of viral infections and the development of innovative antiviral therapies.

Scope of the Special Issue:

Mechanisms of viral infection: Examining how viruses infect host cells, evade the immune system and establish infection, providing insights into the pathogenesis of viral diseases.

Identification of novel antivirals: Presenting cutting-edge research into the discovery of new antiviral compounds, including in vitro and in silico screening methods, and natural products with antiviral properties.

Mode of action of antivirals: Detailed exploration of the mechanisms by which novel antivirals interfere with viral replication, assembly and release, highlighting the molecular targets and pathways involved.

Drug resistance and viral evolution: Discussion of the challenges of viral resistance to existing antivirals and strategies for developing drugs that can overcome these challenges.

Clinical trials and therapeutic potential: Reviews of the progress of novel antivirals in clinical trials, their efficacy, safety and potential impact on the treatment of viral infections.

Future Perspectives: An outlook on the future of antiviral drug development, including emerging technologies, novel approaches and the importance of interdisciplinary research.

Dr. Graciela Andrei
Guest Editor

Manuscript Submission Information

Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.

Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Microorganisms is an international peer-reviewed open access monthly journal published by MDPI.

Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 2700 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.

Keywords

  • viral infection
  • novel antivirals
  • drug resistance
  • viral evolution

Benefits of Publishing in a Special Issue

  • Ease of navigation: Grouping papers by topic helps scholars navigate broad scope journals more efficiently.
  • Greater discoverability: Special Issues support the reach and impact of scientific research. Articles in Special Issues are more discoverable and cited more frequently.
  • Expansion of research network: Special Issues facilitate connections among authors, fostering scientific collaborations.
  • External promotion: Articles in Special Issues are often promoted through the journal's social media, increasing their visibility.
  • e-Book format: Special Issues with more than 10 articles can be published as dedicated e-books, ensuring wide and rapid dissemination.

Further information on MDPI's Special Issue policies can be found here.

Published Papers (1 paper)

Order results
Result details
Select all
Export citation of selected articles as:

Research

24 pages, 2995 KiB  
Article
Hypericin Suppresses SARS-CoV-2 Replication and Synergizes with Antivirals via Dual Targeting of RdRp and 3CLpro
by Helena da Silva Souza, Jéssica Santa Cruz Carvalho Martins, Thiagos das Chagas Sousa, Saiqa Sardar, Natalia Fintelman-Rodrigues, Lina Silva-Trujillo, Thiago Moreno Lopes e Souza, Marilda Mendonça Siqueira, Jorge Hernandes Fernandes and Aline da Rocha Matos
Microorganisms 2025, 13(5), 1004; https://doi.org/10.3390/microorganisms13051004 - 27 Apr 2025
Viewed by 77
Abstract
The continuous emergence of SARS-CoV-2 variants underscores the need for novel antiviral candidates. Hypericin (HY), a compound derived from Hypericum perforatum, exhibited potent in vitro activity against SARS-CoV-2 in Vero E6 cells, with low cytotoxicity (CC50 > 200 nM). HY showed [...] Read more.
The continuous emergence of SARS-CoV-2 variants underscores the need for novel antiviral candidates. Hypericin (HY), a compound derived from Hypericum perforatum, exhibited potent in vitro activity against SARS-CoV-2 in Vero E6 cells, with low cytotoxicity (CC50 > 200 nM). HY showed no significant activity against Influenza A (H1N1) or dengue virus serotype 2, supporting its selective action. Antiviral effects were most evident when HY was administered post-infection, in a concentration-dependent manner, while cellular pretreatment or viral pre-incubation produced limited effects. Notably, HY also displayed virucidal activity, significantly reducing viral titers at 4 °C, 22 °C, and 37 °C. Combination treatments with remdesivir or nirmatrelvir enhanced antiviral efficacy by 50–70% relative to monotherapy, depending on compound concentration. Molecular simulations revealed stable interactions with conserved residues in RdRp and 3CLpro, suggesting a low risk of resistance. Together, these findings highlight the potential of HY as a selective antiviral and virucidal agent against SARS-CoV-2, particularly in combination regimens. Full article
Show Figures

Figure 1

Back to TopTop